EC
SAGE

EntryPoint Capital’s Sage Therapeutics SAGE Stock Holding History

EntryPoint Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-28,502
Closed -$206K – 934
2024
Q3 		$206K Buy
28,502
+15,652
+122% +$143K 0.12% 461
2024
Q2 		$140K Buy
+12,850
New +$165K 0.06% 610
2024
Q1 		– Sell
-7,066
Closed -$153K – 1712
2023
Q4 		$153K Buy
+7,066
New +$140K 0.15% 181

Other funds holding SAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

EntryPoint Capital's SAGE Position: Q4 2024 in Review

EntryPoint Capital sold out of Sage Therapeutics (SAGE) in Q4 2024, closing a stake of 28,502 shares — an estimated $206K sold.

EntryPoint Capital first reported a position in SAGE in Q4 2023 and held it in 3 quarters. The position peaked at $206K in Q3 2024. 177 funds tracked by Wall St. Rank hold SAGE as of Q4 2024.

  • EntryPoint Capital reported no remaining Sage Therapeutics position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 28,502 Sage Therapeutics shares in Q4 2024, an estimated $206K.
  • EntryPoint Capital first reported a position in Sage Therapeutics in Q4 2023 and held it in 3 quarters.
  • EntryPoint Capital's Sage Therapeutics position peaked at $206K in Q3 2024.
  • 177 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.